Values as of: 2024-03-28
COMMON STOCK | Medical Devices |
Last Closing
USD 332.2Change
0.00 (0.00)%Market Cap
USD 9.88BVolume
33.00Analyst Target
N/AVerdict
Verdict
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ABT | Abbott Laboratories |
N/A |
USD 186.58B |
| SYK | Stryker Corporation |
N/A |
USD 133.55B |
| MDT | Medtronic PLC |
N/A |
USD 112.28B |
| BSX | Boston Scientific Corp |
N/A |
USD 107.55B |
| EW | Edwards Lifesciences Corp |
N/A |
USD 55.80B |
| ZBH | Zimmer Biomet Holdings Inc |
N/A |
USD 26.16B |
| STE | STERIS plc |
N/A |
USD 21.09B |
| PHG | Koninklijke Philips NV ADR |
N/A |
USD 18.20B |
| SNN | Smith & Nephew SNATS Inc |
N/A |
USD 10.70B |
| BIO | Bio-Rad Laboratories Inc |
N/A |
USD 7.89B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 3.60% | 55% | F | 50% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 3.60% | 52% | F | 47% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -28.42% | 27% | F | 8% | B- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -28.42% | 27% | F | 8% | B- | ||
| Trailing 5 Years | |||||||
| Capital Gain | 9.64% | 47% | F | 51% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 9.64% | 47% | F | 38% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 8.62% | 60% | D- | 69% | C- | ||
| Dividend Return | 8.62% | 57% | F | 63% | D | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 38.35% | 47% | F | 27% | F | ||
| Risk Adjusted Return | 22.47% | 53% | F | 48% | F | ||
| Market Capitalization | 9.88B | 76% | C+ | 83% | B | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
